Moderna/BioNTech: cancer vaccines will show mRNA not a one-trick pony

After riding high for much of the pandemic, mRNA vaccine pioneers came down to earth in 2022. By mid-June, the share prices of both Massachusetts-based Moderna and Germany’s BioNTech had more than halved. But investors’ excitement was rekindled a few weeks ago when Moderna and partner Merck published a promising set of melanoma trial results. After five decades of failed attempts, cancer vaccines are set for a breakthrough.